Gamma-Guided Breast Biopsy System Cleared by FDA

December 22, 2009 – The FDA has granted 510(k) clearance to a lesion-localization system for molecular imaging biopsy guidance. The GammaLoc (GL) is a complementary technology to Dilon Diagnostics’ 6800 Gamma Camera.

The GL system will help doctors accurately locate breast lesions and enable gamma-guided biopsies. The system utilizes a CorreLocator paddle and a StereoView imaging collimator system - a technique similar to that used in stereotactic X-ray localization. The GammaLoc software calculates the specific location of the suspect lesion. The compact design allows for breast biopsies with better patient comfort and better portability.

For more information: www.dilon.com


Related Content

News | Radiopharmaceuticals and Tracers

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
News | Breast Imaging

April 2, 2024 — iCAD, Inc., a global leader in clinically proven AI-powered cancer detection solutions, announced ...

Time April 02, 2024
arrow
News | Molecular Imaging

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
News | Breast Imaging

March 20, 2024 — Interval breast cancer is one that appears between two reviews of a screening program. That is, it is ...

Time March 20, 2024
arrow
News | Breast Imaging

March 15, 2024 — Screening-detected radial scars without atypia at core-needle biopsy (CNB) have a low upstaging rate to ...

Time March 15, 2024
arrow
News | Breast Imaging

March 6, 2024 — There is a pressing need to explore and understand which social determinants of health (SDOH) and health ...

Time March 06, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 21, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time February 21, 2024
arrow
News | Breast Imaging

February 20, 2024 — Annual breast cancer screening beginning at age 40 and continuing to at least age 79 results in the ...

Time February 20, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 14, 2024 — PanTera, the Belgian joint venture created by IBA and SCK CEN to secure large-scale production of ...

Time February 14, 2024
arrow
Subscribe Now